A detailed history of Rnc Capital Management LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Rnc Capital Management LLC holds 356,760 shares of ABBV stock, worth $60.8 Million. This represents 3.84% of its overall portfolio holdings.

Number of Shares
356,760
Previous 356,760 -0.0%
Holding current value
$60.8 Million
Previous $61.2 Million 15.13%
% of portfolio
3.84%
Previous 3.53%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $2.25 Million - $2.63 Million
14,553 Added 4.25%
356,760 $61.2 Million
Q1 2024

Aug 07, 2024

SELL
$159.82 - $182.1 $6.8 Million - $7.75 Million
-42,562 Reduced 11.06%
342,207 $62.3 Million
Q4 2023

Jan 17, 2024

BUY
$137.6 - $154.97 $21,190 - $23,865
154 Added 0.04%
384,769 $59.6 Million
Q3 2023

Dec 27, 2023

SELL
$133.59 - $154.65 $2.71 Million - $3.14 Million
-20,322 Reduced 5.02%
384,615 $57.3 Million
Q2 2023

Jul 20, 2023

SELL
$132.51 - $164.9 $720,589 - $896,726
-5,438 Reduced 1.33%
404,937 $54.6 Million
Q1 2023

Apr 21, 2023

SELL
$144.61 - $166.54 $2.5 Million - $2.88 Million
-17,312 Reduced 4.05%
410,375 $65.4 Million
Q4 2022

Jan 10, 2023

BUY
$138.31 - $165.87 $295,845 - $354,795
2,139 Added 0.5%
427,687 $69.1 Million
Q3 2022

Oct 18, 2022

BUY
$134.21 - $153.93 $430,679 - $493,961
3,209 Added 0.76%
425,548 $57.1 Million
Q2 2022

Jul 22, 2022

BUY
$137.62 - $174.96 $1.01 Million - $1.29 Million
7,373 Added 1.78%
422,339 $64.7 Million
Q1 2022

Jul 22, 2022

SELL
$131.98 - $163.75 $23 Million - $28.5 Million
-173,907 Reduced 29.53%
414,966 $67.3 Million
Q4 2021

Feb 04, 2022

SELL
$107.43 - $135.93 $303,597 - $384,138
-2,826 Reduced 0.48%
588,873 $79.7 Million
Q3 2021

Nov 02, 2021

BUY
$106.4 - $120.78 $609,246 - $691,586
5,726 Added 0.98%
591,699 $63.8 Million
Q2 2021

Jul 20, 2021

BUY
$105.21 - $117.21 $7.57 Million - $8.44 Million
71,969 Added 14.0%
585,973 $66 Million
Q1 2021

Apr 26, 2021

SELL
$102.3 - $112.62 $977,988 - $1.08 Million
-9,560 Reduced 1.83%
514,004 $55.6 Million
Q4 2020

Jan 13, 2021

SELL
$80.49 - $108.67 $1.51 Million - $2.03 Million
-18,711 Reduced 3.45%
523,564 $56.1 Million
Q3 2020

Dec 03, 2020

SELL
$85.91 - $100.83 $3.24 Million - $3.81 Million
-37,772 Reduced 6.51%
542,275 $47.5 Million
Q2 2020

Jul 23, 2020

BUY
$73.37 - $98.18 $614,106 - $821,766
8,370 Added 1.46%
580,047 $56.9 Million
Q1 2020

Apr 22, 2020

SELL
$64.5 - $97.79 $6.5 Million - $9.86 Million
-100,790 Reduced 14.99%
571,677 $43.6 Million
Q4 2019

Mar 09, 2020

BUY
$72.13 - $90.25 $1.03 Million - $1.29 Million
14,333 Added 2.18%
672,467 $59.5 Million
Q3 2019

Jul 22, 2020

SELL
$62.98 - $75.72 $1.62 Million - $1.94 Million
-25,649 Reduced 3.75%
658,134 $49.8 Million
Q2 2019

Jul 25, 2019

BUY
$65.7 - $83.98 $12.8 Million - $16.4 Million
195,310 Added 39.98%
683,783 $49.7 Million
Q1 2019

Apr 18, 2019

BUY
$77.14 - $90.79 $23,527 - $27,690
305 Added 0.06%
488,473 $39.4 Million
Q4 2018

Jan 15, 2019

BUY
$77.85 - $96.01 $445,924 - $549,945
5,728 Added 1.19%
488,168 $45 Million
Q3 2018

Oct 25, 2018

BUY
$88.91 - $98.84 $367,376 - $408,406
4,132 Added 0.86%
482,440 $45.6 Million
Q2 2018

Jul 20, 2018

BUY
$89.78 - $106.23 $931,018 - $1.1 Million
10,370 Added 2.22%
478,308 $44.3 Million
Q1 2018

Apr 11, 2018

BUY
$92.01 - $123.21 $69,191 - $92,653
752 Added 0.16%
467,938 $44.3 Million
Q4 2017

Jan 17, 2018

SELL
$89.56 - $98.21 $199,629 - $218,910
-2,229 Reduced 0.47%
467,186 $45.2 Million
Q3 2017

Oct 16, 2017

SELL
$69.85 - $89.22 $16.2 Million - $20.7 Million
-231,911 Reduced 33.07%
469,415 $41.7 Million
Q2 2017

Aug 22, 2017

BUY
N/A
701,326
701,326 $50.9 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Rnc Capital Management LLC Portfolio

Follow Rnc Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rnc Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rnc Capital Management LLC with notifications on news.